Advisory Research’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Advisory Research’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,333	Closed	-$1.32M	–	487
2023 Q3	$1.32M	Buy	25,333 +3,412	+16%	+$199K	0.18%	155
2023 Q2	$1.39M	Buy	21,921 +17,515	+398%	+$1.09M	0.18%	159
2023 Q1	$239K	Buy	+4,406	New	+$213K	0.04%	313
2022 Q3	–	Sell	-36,414	Closed	-$2.08M	–	410
2022 Q2	$2.08M	Sell	36,414 -4,141	-10%	-$235K	0.2%	83
2022 Q1	$2.48M	Buy	40,555 +7,451	+23%	+$387K	0.2%	80
2021 Q4	$1.73M	Buy	33,104 +25,165	+317%	+$1.06M	0.14%	134
2021 Q3	$296K	Buy	+7,939	New	+$276K	0.02%	299

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Advisory Research's ITCI Position: Q4 2023 in Review

Advisory Research sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2023, closing a stake of 25,333 shares — an estimated $1.32M sold.

Advisory Research first reported a position in ITCI in Q3 2021 and held it in 7 quarters. The position peaked at $2.48M in Q1 2022. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

Advisory Research reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2023 after selling out during the quarter.
Advisory Research sold 25,333 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $1.32M.
Advisory Research first reported a position in Intra-Cellular Therapies Inc. in Q3 2021 and held it in 7 quarters.
Advisory Research's Intra-Cellular Therapies Inc. position peaked at $2.48M in Q1 2022.
333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.